Indian Nationals Indicted for Smuggling Counterfeit Ozempic
Two men face federal charges for allegedly shipping fake diabetes drugs from China to the United States.
Updated on Sept. 29, 2026 in Drug Crime
Live Poll
Do you trust that current regulations sufficiently protect the drug supply from counterfeit products?
A federal grand jury has indicted Indian nationals Swapnadip Roy and Vicky Ramancha for their alleged roles in an international scheme to smuggle counterfeit Ozempic. The defendants are accused of distributing the fake medication to U.S. markets using fraudulent packaging.
Why it matters
The case highlights federal efforts to curb the distribution of dangerous, unauthorized medical products into the U.S. drug supply. The prosecution underscores the risks posed by counterfeit medications that lack quality oversight.
Swapnadip Roy and Vicky Ramancha face one count of conspiracy, three counts of smuggling, and two counts of selling counterfeit drugs. Roy has already appeared in a Tampa court to enter a plea of not guilty following his extradition from Italy.
The players
Swapnadip Roy
He is a 33-year-old Indian national who was extradited from Italy to the United States to face federal charges.
Vicky Ramancha
He is a 37-year-old Indian national named as a co-defendant in the smuggling conspiracy.
Food and Drug Administration
This federal agency is responsible for protecting public health by regulating the safety and efficacy of medical products.
The details
The defendants allegedly obtained the counterfeit drugs from unauthorized sources in China between July 2023 and April 2024. They reportedly utilized fake labels, inserts, and packaging to ensure the products mimicked genuine Ozempic for distribution to unsuspecting U.S. customers.
Timeline
The alleged smuggling operation commenced in July 2023.
FDA agents seized counterfeit products in December 2023.
The illicit scheme concluded in April 2024.
The federal indictment was publicly announced in September 2026.
Legal Context
The indictment follows established enforcement precedents under the Federal Food, Drug, and Cosmetic Act regarding the sale of misbranded and unapproved drugs. Such cases are becoming increasingly common as authorities target international rings exploiting the high demand for injectable weight-loss and diabetes treatments.
This case serves as a warning for consumers to only obtain prescription medications through licensed pharmacies and verified medical providers. Patients should remain vigilant against suspiciously low-cost or unverified online sources that may distribute dangerous, non-sterile products.
The takeaway
Counterfeit drugs often contain unknown substances that pose severe health risks to those seeking legitimate treatment. Residents should always verify the legitimacy of their prescription sources to avoid receiving harmful, unapproved products.
Further reading
Learn more about local efforts to combat illegal substances in our Drug Crime section.
Live Poll
Do you trust that current regulations sufficiently protect the drug supply from counterfeit products?
